A placebo-controlled, ascending single-dose study to evaluate the safety and pharmacokinetics of VGX-1027 in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2016
At a glance
- Drugs VGX 1027 (Primary)
- Indications Rheumatoid arthritis; Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors VGX Pharmaceuticals
- 01 Mar 2016 Results from this and the other phase I study, published in the Clinical Pharmacology in Drug Development.
- 08 Jan 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 18 May 2007 New trial record.